TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Post Quarterly Financial Result Conference call with investors / analyst22-01-2024
22-01-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Intimation Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201520-01-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201513-01-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Corporate Action-Board to consider Dividend
Intimation of Record Date pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201512-01-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2024 ,inter alia, to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Friday, 02-Feb-24, inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on 31-Dec-23. The Board would also consider payment of Interim Dividend for the year 2023-24.12-01-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201509-01-2024
Buy Torrent Pharmaceuticals; target of Rs 2700: Sharekhan
Sharekhan is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2700 in its research report dated January 05, 2024.08-01-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Acquisition
Intimation of Incorporation of wholly owned subsidiary04-01-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates02-01-2024
TORRENT PHARMACEUTICALS LTD. - 500420 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure u/r 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 201530-12-2023